Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus


Grant Data
Project Title
Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
Principal Investigator
Dr Ho, James Chung Man   (Principal investigator)
Co-Investigator(s)
Professor Ip Mary Sau Man   (Co-Investigator)
Dr Lam Chung Mei Jamie   (Co-Investigator)
Dr Wong King Yan Matthew   (Co-Investigator)
Dr Lam Chi Leung David   (Co-Investigator)
Duration
24
Start Date
2010-04-07
Completion Date
2012-04-06
Amount
51616
Conference Title
Presentation Title
Keywords
non-small cell lung cancer, anaplastic lymphoma kinase
Discipline
Cancer,Respiration
Panel
Medicine
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2010/2011
Status
On-going